1. JAMA. 2014 Mar 26;311(12):1225-33. doi: 10.1001/jama.2014.1873.

Glycated hemoglobin measurement and prediction of cardiovascular disease.

Emerging Risk Factors Collaboration; Di Angelantonio E(1), Gao P(1), Khan H(1), 
Butterworth AS(1), Wormser D(1), Kaptoge S(1), Kondapally Seshasai SR(2), 
Thompson A(1), Sarwar N(1), Willeit P(1), Ridker PM(3), Barr EL(4), Khaw KT(1), 
Psaty BM(5), Brenner H(6), Balkau B(7), Dekker JM(8), Lawlor DA(9), Daimon 
M(10), Willeit J(11), Njølstad I(12), Nissinen A(13), Brunner EJ(14), Kuller 
LH(15), Price JF(16), Sundström J(17), Knuiman MW(18), Feskens EJ(19), 
Verschuren WM(20), Wald N(21), Bakker SJ(22), Whincup PH(2), Ford I(23), 
Goldbourt U(24), Gómez-de-la-Cámara A(25), Gallacher J(26), Simons LA(27), 
Rosengren A(28), Sutherland SE(29), Björkelund C(30), Blazer DG(31), 
Wassertheil-Smoller S(32), Onat A(33), Marín Ibañez A(34), Casiglia E(35), 
Jukema JW(36), Simpson LM(37), Giampaoli S(38), Nordestgaard BG(39), Selmer 
R(40), Wennberg P(41), Kauhanen J(42), Salonen JT(43), Dankner R(44), 
Barrett-Connor E(45), Kavousi M(46), Gudnason V(47), Evans D(48), Wallace 
RB(49), Cushman M(50), D'Agostino RB Sr(51), Umans JG(52), Kiyohara Y(53), 
Nakagawa H(54), Sato S(55), Gillum RF(56), Folsom AR(57), van der Schouw YT(58), 
Moons KG(58), Griffin SJ(1), Sattar N(23), Wareham NJ(1), Selvin E(59), Thompson 
SG(1), Danesh J(1).

Collaborators: Simpson LM, Selvin E, Folsom AR, Coresh J, Wagenknecht L, Barr 
EL, Shaw JE, Zimmet PZ, Magliano D, Knuiman MW, Whincup PH, Wannamethee SG, 
Morris RW, Willeit J, Kiechl S, Santer P, Bonora E, Willeit P, Wald N, Lawlor 
DA, Casas JP, Ebrahim S, Gallacher J, Ben-Shlomo Y, Yarnell JW, Elwood P, 
Casiglia E, Bachman DL, Sutherland SE, Nietert PJ, Cushman M, Selmer R, Håheim 
LL, Søgaard AJ, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R, Benn M, 
Giampaoli S, Palmieri L, Vanuzzo D, Panico S, Balkau B, Bonnet F, Copin N, 
Roussel R, Gómez-Gerique JA, Rubio-Herrera MA, Gutiérrez-Fuentes JA, Simons LA, 
Friedlander Y, McCallum J, Simons J, Price JF, Lee AJ, McLachlan S, Taylor JO, 
Guralnik JM, Phillips CL, Evans DA, Wallace RB, Kohout F, Blazer DG, Cohen H, 
George L, Fillenbaum G, Phillips CL, Guralnik JM, McGloin JM, Khaw K-, Wareham 
NJ, Brenner H, Schöttker B, Müller H, Rothenbacher D, Wennberg P, Jansson J-, 
Hallmans G, Nissinen A, Tuomilehto J, Giampaoli S, Donfrancesco C, Woodward M, 
D'Agostino RB Sr, Daimon M, Oizumi T, Kayama T, Kato T, Danker R, Chetrit A, 
Rosengren A, Wilhelmsen L, Eriksson H, Lappas G, Björkelund C, Bengtsson C, 
Lissner L, Skoog I, Cremer P, Kiyohara Y, Arima H, Ninomiya T, Hata J, Dekker 
JM, Nijpels G, Stehouwer CD, Sato S, Goldbourt U, Kauhanen J, Salonen JT, 
Tuomainen T-, Voutilainen S, Kurl S, Psaty BM, Cushman M, de Boer IH, Bertoni 
AG, Veschuren WM, Rosengren A, Kuller LH, Gillum RF, Sato S, Bakker SJ, Dullaart 
RP, Lambers Heerspink HJ, Hilege HL, Moons KG, van der Schouw YT, Jukema JW, 
Sattar N, Trompet S, Stott DJ, Dagenais GR, Cantin B, Barrett-Connor E, Gudnason 
V, Kavousi M, Dehghan D, Hofman A, Franco OH, Tunstall-Pedoe H, Umans JG, Lee E, 
Best L, Howard BV, Onat A, Can G, Ademoğlu E, Nakagawa H, Sakurai M, Nakamura K, 
Morikawa Y, Njølstad I, Løchen M-, Mathiesen EB, Wilsgaard T, Sundström J, 
Byberg L, Cederholm T, Olsson E, Wassertheil-Smoller S, Howard BV, Brunner EJ, 
Ridker PM, Pradhan AD, Cook NR, Ford I, Marín Ibañez A, Feskens EJ, Kromhout D, 
Walker M, Watson S, Burgess S, Butterworth AS, Di Angelantonio E, Gao P, Gregson 
J, Harshfield E, Kaptoge S, Khan H, Pennells L, Spackman S, Thompson SG, Walker 
M, Warnakula S, Willeit P, Wood AM, Wormser D, Danesh J.

Author information:
(1)University of Cambridge, Cambridge, United Kingdom.
(2)St George's University of London, London, United Kingdom.
(3)Brigham and Women's Hospital, Boston, Massachusetts.
(4)Baker IDI Heart and Diabetes Institute, Victoria, Australia.
(5)University of Washington, Seattle6Group Health Research Institute, Seattle, 
Washington.
(6)German Cancer Research Center, Heidelberg, Germany.
(7)Inserm, Villejuif, France9University Paris-Sud, Villejuif, France.
(8)Vrije Universiteit Medical Center, Amsterdam, the Netherlands.
(9)University of Bristol, Bristol, United Kingdom.
(10)Yamagata University, Japan.
(11)Medical University Innsbruck, Austria.
(12)University of Tromsø, Tromsø, Norway.
(13)National Institute of Health and Welfare, Helsinki, Finland.
(14)University College London, London, United Kingdom.
(15)University of Pittsburgh.
(16)University of Edinburgh, Edinburgh, United Kingdom.
(17)Uppsala University, Uppsala, Sweden.
(18)University of Western Australia, Perth, Australia.
(19)Wageningen University, Wageningen, the Netherlands.
(20)National Institute for Public Health and the Environment (RIVM), Bilthoven, 
the Netherlands.
(21)Wolfson Institute of Preventive Medicine, London, United Kingdom.
(22)University of Groningen, University Medical Center Groningen, the 
Netherlands.
(23)University of Glasgow, Glasgow, United Kingdom.
(24)Sheba Medical Center, Tel Hashomer, Israel.
(25)Hospital 12 de Octubre, Madrid, Spain.
(26)Cardiff University, Cardiff, United Kingdom.
(27)University of New South Wales, Kensington, Australia.
(28)Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
(29)Medical University of South Carolina, Charleston.
(30)University of Gothenburg, Gothenburg, Sweden.
(31)Duke University Medical Center, Durham, North Carolina.
(32)Albert Einstein College of Medicine, New York, New York.
(33)University of Istanbul, Istanbul, Turkey.
(34)San Jose Norte Health Centre, Zaragoza, Spain.
(35)University of Padova, Padova, Italy.
(36)Leiden University Medical Center, Leiden, the Netherlands.
(37)University of Texas School of Public Health, Houston.
(38)Istituto Superiore di Sanità, Rome, Italy.
(39)Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, 
Copenhagen, Denmark.
(40)Norwegian Institute of Public Health, Oslo, Norway.
(41)Umeå University, Umeå, Sweden.
(42)University of Eastern Finland, Kuopio, Finland.
(43)University of Helsinki, Helsinki, Finland.
(44)The Gertner Institute for Epidemiology and Health Policy Research, Tel 
Hashomer, Israel47Tel Aviv University, Tel Aviv, Israel48The Feinstein Institute 
for Medical Research, New York, New York.
(45)University of California, San Diego.
(46)Erasmus Medical Center, Rotterdam, the Netherlands.
(47)Icelandic Heart Association, Reyjavik, Iceland52University of Iceland, 
Reykjavik, Iceland.
(48)Rush University Medical Center, Chicago, Illinois.
(49)University of Iowa College of Public Health, Iowa City.
(50)University of Vermont, Burlington.
(51)Boston University, Boston, Massachusetts.
(52)Georgetown University Medical Centre, Washington, DC.
(53)Kyushu University, Kyushu, Japan.
(54)Kanazawa Medical University, Ishikawa, Japan.
(55)Osaka Medical Center for Health Science and Promotion/Chiba Prefectural 
Institute of Public Health, Osaka, Japan.
(56)Howard University, Washington, DC.
(57)University of Minnesota, Minneapolis.
(58)Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrecht, Utrecht, the Netherlands.
(59)Johns Hopkins University, Baltimore, Maryland.

IMPORTANCE: The value of measuring levels of glycated hemoglobin (HbA1c) for the 
prediction of first cardiovascular events is uncertain.
OBJECTIVE: To determine whether adding information on HbA1c values to 
conventional cardiovascular risk factors is associated with improvement in 
prediction of cardiovascular disease (CVD) risk.
DESIGN, SETTING, AND PARTICIPANTS: Analysis of individual-participant data 
available from 73 prospective studies involving 294,998 participants without a 
known history of diabetes mellitus or CVD at the baseline assessment.
MAIN OUTCOMES AND MEASURES: Measures of risk discrimination for CVD outcomes 
(eg, C-index) and reclassification (eg, net reclassification improvement) of 
participants across predicted 10-year risk categories of low (<5%), intermediate 
(5% to <7.5%), and high (≥ 7.5%) risk.
RESULTS: During a median follow-up of 9.9 (interquartile range, 7.6-13.2) years, 
20,840 incident fatal and nonfatal CVD outcomes (13,237 coronary heart disease 
and 7603 stroke outcomes) were recorded. In analyses adjusted for several 
conventional cardiovascular risk factors, there was an approximately J-shaped 
association between HbA1c values and CVD risk. The association between HbA1c 
values and CVD risk changed only slightly after adjustment for total cholesterol 
and triglyceride concentrations or estimated glomerular filtration rate, but 
this association attenuated somewhat after adjustment for concentrations of 
high-density lipoprotein cholesterol and C-reactive protein. The C-index for a 
CVD risk prediction model containing conventional cardiovascular risk factors 
alone was 0.7434 (95% CI, 0.7350 to 0.7517). The addition of information on 
HbA1c was associated with a C-index change of 0.0018 (0.0003 to 0.0033) and a 
net reclassification improvement of 0.42 (-0.63 to 1.48) for the categories of 
predicted 10-year CVD risk. The improvement provided by HbA1c assessment in 
prediction of CVD risk was equal to or better than estimated improvements for 
measurement of fasting, random, or postload plasma glucose levels.
CONCLUSIONS AND RELEVANCE: In a study of individuals without known CVD or 
diabetes, additional assessment of HbA1c values in the context of CVD risk 
assessment provided little incremental benefit for prediction of CVD risk.

DOI: 10.1001/jama.2014.1873
PMCID: PMC4386007
PMID: 24668104 [Indexed for MEDLINE]